This is the problem with the clinical trial process.
IF they are showing signs of success, IF there are
side effects, but 'minor' like shot site flaring up.
Why now allow them to do a 'phase 4' type of trial vs
running a PH 3. They could start 'treating' folks who are
willing to 'try' and record the observations as 'clinical' data
(redefine what and how its collected for each one trying it.
Won't be perfect, but if someone can't walk 10 meters, and then
can, who cares how long it took him for example.
Or couldn't open their hand for years, but now can? Who cares
how far he can, if he can flatten his palm, et al
I was kind of wondering if the fdA might work with them to speed up
the potential approva IF visible results are being seen.
But alas, this is the current timeline which of course likely means the
current share count of 80 Mil goes up (ATM) due to a need for funding
in order to survive till the trial is over in the 1st half of 2028. This is just
too long for something they are already seeing results that can't be
challenged.
Prepare for Pivotal Phase 3 Study Initiation: Expected Mid-2026
• Expected Completion of Enrollment in 2H 2027 with Topline Data in 1H 2028
Disclaimer: been a long time since i owned any, dilution and getting in way too early
aren't a winning combination. And hate it when the Market Cap gets run up this early..
Market Data 
Markets 
AI
